What is it about?
A major barrier in the diagnosis and clinical monitoring of Alzheimer’s disease is the lack of safe and accessible diagnostic tools. This paper describes a novel class of compounds that address Such agents may enable the safe, noninvasive MRI detection of the amyloid-beta peptide, the primary causative agent of Alzheimer’s disease.
Featured Image
Why is it important?
A major barrier in the diagnosis and clinical monitoring of Alzheimer’s disease is the lack of safe and accessible diagnostic tools.
Perspectives
A lot of fun science as we explored new ideas in chemistry and magnetic resonance. We look forward to testing in vivo and developing additional spin-labeled compounds for detecting the Alzheimer's amyloid peptide.
Prof. John C Voss
University of California Davis
Read the Original
This page is a summary of: A Metal-Free Method for Producing MRI Contrast at Amyloid-β, Journal of Alzheimer s Disease, December 2016, IOS Press,
DOI: 10.3233/jad-160279.
You can read the full text:
Contributors
The following have contributed to this page
